News
16 May 2017
Friulchem S.p.A. Issued Patent for Rifaximin
Friulchem S.p.A., a chemical-pharmaceutical company
active in human and veterinary fields, has received an US Patent (US Patent
14/11856) covering own solid form called “pseudo-crystalline” solid form,
derived from Rifamycin O.
Rifaximin is approved for the treatment of travelers'
diarrhea in adults and in children 12-years of age and older. Rifaximin has
also been evaluated for the treatment of hepatic encephalopathy, infectious
diarrhea, diverticular disease and as an antibacterial prophylactic prior to
colon surgery.
Friulchem and its partners started the development of finished product both in human and veterinary fields.
Under granting there are also EU patent n. 12721559.8 and MX patent n. MX/A/2013/013463.
Mentioned Companies
FRIULCHEM S.P.A.
